Key Points
- Major shareholder Ventures V. L.P. 5Am sold 52,317 Entrada Therapeutics shares at an average $6.85 each, generating $358,371.45 and reducing its stake by 1.84% while retaining 2.78 million shares.
- Entrada Therapeutics reported a quarterly loss of $1.01 per share, missing estimates by $0.04, while revenue of $0.90 million fell well short of the $2.32 million consensus forecast.
- TRDA shares opened at $6.95 and remain well below their 52-week high of $16.45; analysts have a consensus “Hold” rating with an average price target of $17.50.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures L.P. 5Am sold 10,494 shares of Entrada Therapeutics stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00. Following the completion of the transaction, the insider owned 2,836,098 shares in the company, valued at approximately $19,852,686. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Entrada Therapeutics Stock Performance
Shares of NASDAQ:TRDA opened at $6.95 on Tuesday. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.45. The stock has a fifty day moving average of $6.86 and a 200-day moving average of $9.68. The company has a market capitalization of $270.63 million, a PE ratio of -1.76 and a beta of -0.26.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. As a group, research analysts forecast that Entrada Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Entrada Therapeutics in the 2nd quarter worth about $19,013,000. Millennium Management LLC lifted its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company's stock valued at $4,852,000 after buying an additional 666,287 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company's stock valued at $1,947,000 after buying an additional 235,384 shares during the last quarter. Baker BROS. Advisors LP grew its stake in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company's stock valued at $52,148,000 after buying an additional 206,911 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its stake in shares of Entrada Therapeutics by 115.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company's stock valued at $1,670,000 after buying an additional 154,143 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.
Analyst Upgrades and Downgrades
TRDA has been the topic of a number of analyst reports. Weiss Ratings cut Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Thursday, June 11th. Roth Capital set a $10.00 target price on shares of Entrada Therapeutics in a report on Friday, May 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, May 8th. Finally, Guggenheim cut their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, June 8th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $17.50.
Read Our Latest Stock Report on Entrada Therapeutics
More Entrada Therapeutics News
Here are the key news stories impacting Entrada Therapeutics this week:
- Negative Sentiment: Major shareholder Ventures V. L.P. 5Am reported selling 62,811 shares across August 6 and August 7 for approximately $431,829. The transactions reduced its reported ownership by about 2.2%, signaling some disposition of shares. SEC filing on Ventures V. L.P. 5Am share sales
- Negative Sentiment: Director Kush Parmar reported selling 155,255 shares in three transactions from August 6 through August 10 for approximately $1.08 million. The sales reduced his position by roughly 5.5%, adding to concerns about insider confidence in the near term. SEC filing on Kush Parmar share sales
- Neutral Sentiment: Despite the sales, the filings indicate that Ventures V. L.P. 5Am and Parmar continued to hold millions of TRDA shares, so the transactions represent relatively modest reductions in their overall stakes rather than complete exits.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
